The Physician and the Pharmaceutical Industry in th 0iJnited StatS/ By L. W. FROHLICH New York, U.S.A. IT would be indiscreet of me to overlook the early spiritual ancestry claimed by the pharmaceutical industry, but in the interest of history, I must emphasize the tremendous difference between the products of the pharmaceutical art then and now. For almost two thousand years, the most reliable products of the apothecary's art-however well-intentioned the pharmacistswere either ineffective or poisonous. By 1900 pharmacology had, of course, become considerably more beneficent in its offerings. Digitalis, ergot, iodine, calomel and quinine were all recognized as having specific therapeutic effects. But their total contribution to the general welfare was at best peripheral. To speak of a pharmaceutical industry at all-even as late as 1910-is to exaggerate seriously the significance of drugs to medicine at that time. Patience, humility and understanding were more essential to the practice of medicine than the greater part of the physician's pharmacology.
A new era began with Ehrlich's synthesis of arsphenamine, with the isolation of insulin by Banting and Best, and with the techniques for the control of pernicious anemia developed by Minot, Murphy and Whipple. But the history FIG. 1.-Consumer-spending for prescriptions. (Annual Prescription Survey, Drug Topics. New York, 1960.) AUGUST of the pharmaceutical industry is not quite parallel; nothing that happened before the 1930s was even a preparation for the developments that followed Dr. Gerhard Domagk's paper in 1935 which launched the sulphonamides. With the stimulus of the 2nd World War, a major industry arose within a few years. The advent of penicillin-one of England's monumental contributions to modern therapy-was the most startling evidence of this new stature. In 1943 the American pharmaceutical industry produced 29 pounds of the miraculous new powder. By July 1944 one month after D-Day-it was being produced in sufficient volume to supply adequately the Allied Invasion Forces. To-day, we are living in the midst of a pharmacological revolution. The concept of conscious, directed effort to develop specific drugs to combat specific diseases, or to fill specific needs, has captured the imagination of all. While there was no spectacular increase in the consumption of drugs between 1930 and 1938, Fig. 1 shows the phenomenal rate of growth since then.
By 1959, ethical drug sales had increased almost three times as much as the increase in Gross National Product (Fig. 2) . 
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Even more important than mere growth to the character of the modern pharmaceutical industry has been the fantastic proliferation of products. Indeed, the development of new products has been far and away the largest factor in the growth. The changes in the categories of drugs available in the decade 1950-1959 are emphasized by comparison of the United States Pharmacopeia XIV, 1950, and the United States Pharmacopeia XV, 1955 . The latter shows an increase of almost 250 new drugs which were not present in its predecessor. The new Pharmacopeia, now in the press and due for publication this year, will show an even more impressive figure (Fig. 3 , 1955 -1959 . (De Haen, P., 1960 from 1955 to 1959. In addition, more than a thousand new combinations were introduced.
The product increase can be shown another way. Fig. 5 shows the effect of new products on the physician's prescribing habits in five therapeutic categories that together account for approximately one-third of prescription sales. Fig. 5 actually understates the impact of new drugs because even where a particular category did exist fifteen years ago, the drugs prpscribed FIG. 3.-Changes in categories of drugs, 1950 -1955 . (Kramer, L. M., 1958 Hlth. Rep., Wash., 73, 929.) A great many preparations, for example the corticosteroids and the tranquillizers, have appeared in entirely new therapeutic fields during the last decade, and provide therapeutic approaches to a multitude of diseases for which there was largely no effective treatment ten years ago.
The acceleration rate in the development of new products is enormous. The pharmaceutical industry has developed and introduced over 400 new chemicals since 1950.
This amounts to a completely new product almost every week.
There has, of course, been substantial acceleration within this period; of these 400-odd new chemicals, 63 were introduced during the last year. Fig. 4 shows the number of new products introduced on a national scale in five years- to-day within that category are apt to be recent developments. For example, about 45 % of those now receiving drug therapy for diabetes are on oral antidiabetic preparations, and the trend for their use seems to be upward. It is estimated that 60% of newly discovered diabetics receive oral therapy.
What I wish to point out by these statistics are the consequences of this rate of growth upon the industry responsible for it. These consequences can hardly be exaggerated. It is not too much to say that every characteristic of the pharmaceutical industry unique to it is the result of this rate of growth.
The pharmaceutical industry is a product of quick planning, on-the-spot executive decisions, rapid action, and sometimes of improvisation, although this does not imply a lack of careful thinking.
The most important characteristic of the pharmaceutical industry arising out of rapid growth is, of course, the central place that research holds in the total structure of the whole industry. As shown in Fig. 6 , the pharmaceutical industry has spent about $600,000,000 on research in the past four years. This comes to about 7 5 % of sales for the period. And even in so short a time, the acceleration in growth rate that is the major characteristic of the pharmaceutical industry is apparent. In 1960, it is estimated that $200,000,000 will be spent in the search for new drugs, comprising about 9 % of sales. This is probably unparalleled by any industry at any time.
FIG. 6.-Pharmaceutical industry-research expenditures. (Science Information l,ureau, 1959, New Medical Materia, 1, 22.) An immense percentage of this great expenditure goes to-day into basic research-so much, indeed, that the line between basic research and applied research is becoming indistinct. For the pharmaceutical industry research is more than a sound investment; it is imperative for survival. The amount of money expended upon basic research by it is out of all proportion to that spent by other industries. In a survey made in 1955 it was found that 500 companies had contributed to fundamental research by the publication of scientific articles in the broad field of chemistry, including metallurgy, 'solid state and nuclear physics, and certain branches of biology and physiology. However, 59 companies accounted for over two-thirds of the total number of publications. Obviously, basic research is a major function of these companies. It is notable that more than one-fourth of these 59 companies were pharmaceutical houses. Table I shows that the pharmaceutical industry produced two-thirds as many papers as the chemical industry, ten times its size, and it produced about as many papers as the petroleum and electrical industries, both much larger than itself. The most significant figure, perhaps, is the number of scientists per 1,000 employees-4 5 in pharmaceuticals as compared to the next industry, the chemical, with 1 27. The significance of research is shown even more strikingly in Fig. 7 . Here we observe that the size has little to do with the intensity of effort in basic research in the pharmaceutical industry.
The smaller companies-with from 1,000 to 5,000 employees-exert as much effort proportionately in basic research as do the largest. As may be seen in the lower bar graph, this situation does not exist in the rest of the chemical industry.
Basic research is, of course, a long way from constituting the whole interest of the industry. Applied research is still the larger item in its budget. If, to-day, one were to corner the drug market as it were-if one should have, all at one time, the top prescription drugs in the ten largest drug categories-and if one should abandon research as a consequence, one's company would surely be out of business in a few years. The result of this unique situation is a competitive zeal in the pharmaceutical industry which would have warmed Adam Smith's heart. The whole future of the company-for good or ill-is at all times in the laboratory, and past achievement is a very shaky foundation indeed. One needs only to remember how few of the drugs used in the 1940s are still in use in the same form and manufactured by the same company to-day. Acceleration in innovation means an acceleration in obsolescence, and to-day's prescription drugs become obsolete twice as fast as they did ten years ago. In 1958 one-fifth of the drugs dropping out of the "frequently prescribed" class were less than 3 years old, and about onehalf were less than 5 years old.
Where major new research findings can be anticipated, as in heart disease, it is likely that every major pharmaceutical house has some sort of relevant project going. And in these races the consolation prizes are not very consolingrewards are very much to the swift. A new drug is hence not only a remedy or help to patients and physicians, but also a source of informationor at least stimulation-to competitors. Hence, it is not solely efficacy and availability that measures drug life from the date of introduction. The day a drug is marketed it invites other firms to do better and very often it implies a method to go about this. The result is that speed of marketing is life and death to the pharmaceutical manufacturer. The day a product is marketed he may have available, theoretically, 100% of the market. Within a relatively short time, competition will significantly limit the extent of this market. So the pharmaceutical manufacturer must always work in terms of two indeterminate lengths of time-the interval between the beginning of a research project and full production of the product of that research (if production is justified), and the interval between marketing and obsolescence. There is inherent in this situation an invitation to manufacturers to beat the clock which ticks off the hours with such finality, and there is far too little understanding of this by the uninformed, outside observers. Quite clearly, this pressure of time is of considerable advantage to the ultimate consumer.
One of the most painful situations in medical history, occurring again and again, is the one in which a valuable discovery lies unrecognized for years after its first description because it fails to become generally known. In 1847 Sir Benjamin Brodie acknowledged that some means to make surgical procedures painless was among the greatest needs of mankind, but he said at the same time that he thought the wish for such a technique chimerical. But we know that ether anesthesia had already been demonstrated the year before by Morton, and five years before by Long and Jackson. Even worse, Sir Humphry Davy had written in the year 1800 -forty-seven years before-that "as nitrous oxide in its extensive operation seems capable of destroying physical pain, it may probably be used with advantage during surgical operations". And yet Sir Benjamin Brodie was one of the great surgeons of his time, and presumably one of the best informed.
But one need not go so far back. As you know, sulphanilamide-the effective part of the compound described by Domagk-had been synthesized by Paul Gelmo in 1908, and penicillin had been studied by Sir Alexander Fleming fourteen years prior to its introduction into clinical use. As useful a drug as aspirinrelatively unknown to the public in 1919-was really discovered in 1883. These intervals between discovery and general acceptance are periods of incalculable pain-of waste of human energy, of distorted and frequently shortened human lives. We are inclined, I think, to forget the positive value of urgency in pharmacology. The optimum intervals between discovery and production-between production and general use-are the shortest intervals consonant with safety and reliability, Every day these periods are prolonged unnecessarily may mean a day of pain, and the possibility of premature death. For the individual manufacturer, the sense of urgency stems also from the necessity of speed to ensure survival. He must communicate his successes to the ohly individual able to translate 582 4 ably on the advice of his physician. His is a heavy schedule. How is the physician supposed to keep up with new developments while working fifty or sixty hours a week? Fig. 9 shows the extent of the problem. Of the 205,000 practising physicians in the United States, only about 46,000 are not in private practice. This group includes hospital staff physicians, teachers in medical schools, researchers and public health officers. Of the 159,000 physicians in private practice, less than half-76,000-limit their practice to a specialty. This leaves 83,000 physicians who are in general practice, although 22,000 of these also specialize. Now it is precisely the general practitioner whose professional interests must be broadest, and to whom the greatest number of new discoveries are apt to be relevant. Fig. 10 gives us a personal them into public benefaction-the practising physician. Is this gentleman in the optimum condition to receive and act upon the good news? Fig. 8 makes the basic facts clear.
The average American physician works fifty hours or longer a week. In his most active period-usually before the age of 45-he is apt to work more than sixty hours a week. Reduction from this peak is ordinarily made deliberately when the physician is about 50 years old-prob- He is the hardest-working individual in the medical profession, working a significantly greater number of hours per week than the specialist. That he has little time for leisure will be even more evident when looking at Figs. 11 and 12 which describe two typical types of practice in a one-year period.
It might be interesting at this point to learn how this busy practitioner regards his way of life. Physicians were asked if they would like their children to study medicine. The responses indicated in Fig. 13 reflect his feeling that his work is rewarding and satisfying. news there is. Consequently, major medical meetings are thoroughly covered by all of the major news media, and any new discovery is guaranteed extensive coverage. This is one of the most critized elements in the total medical scene to-day, and some of this criticism may be just. No physician relishes the prospect of hearing about new drugs from his patients, and this can easily happen to a busy doctor.
We have then a new industry, essentially, for which time is a crucial factor in every stage of its operation, which needs to make its achievements known to one of the busiest groups of people in the world-to a group which needs to FIG. 11. -One year's general practice. (Seidenstein, H. R., 1957 . N. Y. St. J. Med., 57, 2827 And yet his need to be informed is also urgent. In the climate of opinion that has been created in the course of the last twenty years, to describe a physician as up to date is no longer to praise him highly-it is to attribute to him an indispensable characteristic. In additionJto his professional conscience, public opinion forces him to this. A major force in medicine to-day in the United States is the interest that the average man takes in its progress. For something like 40% of the great number of newspaper readers, medical news is the most interesting kind of Fig. 14. To the question, "Where did you get the information about the last new drugs you prescribed ?"-a majority of the physicians interviewed mentioned commercial sources. With regard to medical journals, however, many Patients respondents did not distinguish between articles 5 f ts and advertisements. I do not mean to minimize the value of professional publications or professional meetings. They have an important nkice since thev organize and relate available FIG. 12. One year's rural practice. L. J., 1955, G.P., 12, September information on specific diseases and usually, in part, concern themselves with the evaluation of (Taubenhaus, new data. This has always been the case. When * , p. 97.) this Society met on June 10, 1807, only one of four items on the agenda was a specific-the use of cold in gout. The other three subjects discussed were chronic croup, tinea capitis, and hydrophobia in a horse-all specific conditions admitting of a variety of remedies.
For the manufacturer, the professional publications as a means of introducing new products often have the fatal disadvantage of time lag. An interval of from six months to a year and a half, or more, is customary between the submission of an article and its publication. In terms of what has already been said, one can imagine the anxiety of the manufacturer at the thought of such delay. And, from the point of view of the average physician also, journals have limitations. In the first place, there are so many of them. There are scores of major journals in the United States, containing a substantial amount of information important to the general practitioner. And one must keep in mind the quantity of new products which he must, in one way or another, evaluate.
I do not need to belabour the conclusion I think must be drawn from this survey of the relationship of the pharmaceutical industry to the modern physician. I believe that responsible medical communication is the irreplaceable bridge between them. There is no other present means of contact so swift and so concise, and we must never forget that the most rapid therapeutic application consistent with safety is to everyone's advantage.
From time to time, one may take exception to a strong pharmaceutical message-and I quote:
"There has been much complaint of late years of growth, both in the world of trade and in that of intellect, of quackery, and especially of puffing: but nobody seems to have remarked that these are the inevitable fruits of immense competition; of a state of society, where any voice, not pitched in an exaggerated key, is lost in the hubbub. Success, in so crowded a field, depends, not upon what a person is, but upon what he seems: mere marketable qualities become the object instead of substantial ones, and a man's labour and capital are expended less in doing anything than in persuading other people that he has done it."
This was written by John Stuart Mill almost a hundred years ago, and not too much seems to have changed since then. But the pharmaceutical industry-all over the world-has good justification for making its voice heard, and for being proud of its achievements.
Again, let me say that I do not regard the present state as the ideal one, and I think the pharmaceutical industry has never refused to entertain the suggestion that things might be improved. But I wish to make it clear that its whole structure is determined by the conditions under which it has grown up, and I am absolutely convinced that the structure itself has proven its value to the public at large.
For the manufacturer of pharmaceuticals, marketing is a sequence in which each step requires fresh and crucial decisions. Products have life cycles, as Fig. 15 shows.
The period of product introduction is particularly important as it is ordinarily a period of loss, and the amount spent initially often greatly exceeds revenue from sales. Communications in this period are designed to acquaint the FIG. 15. -Typical life cycle of a product. (Forrester, , J. W., 1959, Harv. Business Rev., 37, 100.) largest possible number of physicians with the nature of the product and its applicability to their patient problems.
The second period is the period of market growth in which the aim is to cover the potential market as thoroughly as possible, with emphasis on the experiences gained in the first phase.
The first two periods may not be periods of intense competition (although competition does sometimes appear in the second period) but the third period-market maturity-is a critical one from every point of view, because in this period training of the physician: to study, observe, and form conclusions.
The last chart- Fig. 16 -which is based on a study of 5,000 physicians made in 1956, and a comparison with a study made only a few weeks ago shows that the relationship between the physician and the pharmaceutical industry in the United States is an excellent one.
I would not underrate the moral problems implicit in the very existence of the pharmaceutical industry. There is a difference between professional and business ethics. The professional FIG. 16 .-Has the pharmaceutical industry established a mutually beneficial relationship with physicians? (Science Information Bureau, 1956 and 1960, Surveys of General Practitioners. New York.) similar products have usually been introduced, and at this point the physician must make his choice. As you can see, this can be the beginning of the end of the life cycle, for economic, competitive or technological reasons.
Sometimes at this point the only thing that helps product survival is the ingenuity of the manufacturer and the reputation and image he has created with the physician for quality and service. The physician respects the integrity of the manufacturer, usually because he has seen the product perform in his own clinical experience. This is why the conscientious pharmaceutical manufacturer is very hesitant ever to present an unrealistic picture. Two things work to minimize the hazard of overstated claims. One of them is concern for the manufacturer's reputation-physicians have long memories. The other factor is the development of a kind of community opinion among physicians, which is probably as reliable an index to the usefulness of a drug as there is. May we never overlook the man must operate in terms of a very rigorous standard of professional conduct because his power in relationship to patients is so great. The businessman is of much less immediate consequence to his customers ordinarily, and hence the standard of public responsibility set for him need not be nearly so high. The drug business is in an intermediate position. Its responsibility for the health of its customers is awesome, but it is an indirect responsibility. All of its ambiguities arise from this fact. It is a business, but it is a business which is more than ordinarily susceptible-and properly so-to public attention.
However, I think the most intensive scrutiny will show that it is sound and functions properly in all of its essentials. It is not a static creationit is a growth-determined in all of its essential characteristics by the dynamic situation in which it lives. So long as this exists, the physicianpharmaceutical industry relationship will remain essentially sound, especially since each needs the other.
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